Icon

Diovan HCT - (80,160,320mg/12.5mg , 160,320mg/25mg; Tablet)

Valsartan and Hydrochlorothiazide Novartis
80,160,320mg/12.5mg , 160,320mg/25mg; Tablet
More Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
More Than 5
More Than 5
Indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
Yes
***** ** *** *** **** **** ** *** ******** ********* ******** ** *** **, ****. ***** ** ******** ** ****** *** **** ** **** **, **** ********* ****** ** ****** '***. ******* **** ******** ********* ******** ** *** **, ****. ***** ******** ******** ***** *** **** ** . ******* ******** ******** ***** *** **** **.
Diovan HCT Patent 1
***** *** *********
******* *** *********
***** *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** *** ********* *** ********* ******** ******** ** **** **, ****
******* ** \ ** *** ********* *** ********* ********* ******** *** ****** *** ****
***** ** \ ** *** **, **** ******* ******** ******** ** ***** **, ****
  1. : ***** ******** ******** ***** *** **** ** .
  2. *** **, **** : ***** *** ********* ********
  3. : ******* ******** ******** ***** *** **** **.
  4. ***** **, **** : ******* *** ********* ********
  5. **** *, **** : ***** ******** ******** ***** *** **** **** **** ** *********** ****** '*** ******** ** **** **, ****
  6. **** **, **** : ******** **** ***** ** ******** ***** ** *** ******.
  7. **** **, **** : ***** ******** *** **** ** ***.
  8. *** **, **** : ********** ********* **** *****
  9. *** *, **** : ****** ******** ** ********** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.